Online citations, reference lists, and bibliographies.

Paramagnetic Micro-particles As A Tool For Rapid Quantification Of Apixaban, Dabigatran, Edoxaban And Rivaroxaban In Human Plasma By UHPLC-MS/MS

M. Wiesen, Cornelia Blaich, T. Streichert, G. Michels, C. Müller
Published 2017 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Abstract Background: Assessment of the anticoagulant activity of direct oral anticoagulants (DOACs) is justified in special clinical situations. Here, we evaluated two independent extraction methods and developed a multi-analyte ultra-high performance liquid chromatography tandem mass (UHPLC-MS/MS) method for the quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma. Methods: Routine extraction based on protein precipitation with acetonitrile and subsequent centrifugation was compared to sample clean-up using commercial paramagnetic micro-particles and subsequent magnetic depletion. Stable isotope-labeled analogs of all analytes were employed as internal standards. The method was validated according to international guidelines in terms of linearity, precision, trueness, sensitivity, recovery and matrix effects. The performances of both extraction methods were assessed in clinical samples obtained from patients treated with either apixaban or rivaroxaban. Additionally, we report on a patient with nonadherence to rivaroxaban treatment and fulminant pulmonary embolism. Results: The method was linear from 2 to 500 ng/mL for all analytes, and quantification of DOACs was established within a run time of 2.0 min. Based on MS/MS analyte responses, relative matrix effects were better controlled for dabigatran after extraction with paramagnetic micro-particles. Internal standards fully compensated for recovery and matrix effects in all assays, yielding equivalent results for both methods. Apixaban and rivaroxaban concentrations determined in clinical samples after extraction with both methods were in good agreement (R2=0.990). Conclusions: A rapid and accurate multi-component UHPLC-MS/MS method for the quantification of four DOACs in human plasma was established. Paramagnetic micro-particles appear suitable for clean-up of plasma samples for LC-MS/MS-based therapeutic drug monitoring purposes.
This paper references
10.1016/j.thromres.2014.06.016
On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation.
M. Skeppholm (2014)
10.1016/j.jchromb.2015.02.042
Development and validation of LC-MSMS assay for the determination of the prodrug dabigatran etexilate and its active metabolites in human plasma.
Eman G. Nouman (2015)
10.1515/cclm-2014-1108
Multi-analyte analysis of non-vitamin K antagonist oral anticoagulants in human plasma using tandem mass spectrometry
Cornelia Blaich (2015)
10.1016/j.thromres.2016.01.012
Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery.
M. Schellings (2016)
10.1515/cclm-2014-0767
Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?
G. Lippi (2015)
10.4155/bio.15.261
Validation of an LC-MS/MS method for the simultaneous quantification of dabigatran, rivaroxaban and apixaban in human plasma.
S. Baldelli (2016)
10.1016/j.amjmed.2016.05.041
Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy.
M. Barra (2016)
10.1007/s00228-013-1504-x
Therapeutic drug monitoring for tomorrow
E. Eliasson (2013)
10.1097/MOH.0b013e328363c170
Treatment with novel oral anticoagulants: indications, efficacy and risks
Shari Ghanny (2013)
10.1111/nyas.12567
Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation.
M. Hanna (2014)
10.1016/j.thromres.2015.05.001
Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review.
D. Adcock (2015)
10.1373/clinchem.2015.251272
Clinical Mass Spectrometry-Achieving Prominence in Laboratory Medicine.
T. Annesley (2016)
10.1016/j.clinbiochem.2013.01.003
Deproteination of serum samples for LC-MS/MS analyses by applying magnetic micro-particles.
Katrin König (2013)
Bereitgestellt von | Universitäts-und Stadtbibliothek Köln Angemeldet | martin.wiesen@uk-koeln.de Autorenexemplar Heruntergeladen am | 23.03
10.1124/dmd.107.019083
The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans
S. Blech (2008)
10.1373/clinchem.2014.232207
To monitor dabigatran or not: a matter of patient safety.
Hemamalini Ketha (2015)
10.1016/J.CLINBIOCHEM.2004.11.007
Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry.
P. Taylor (2005)
10.1002/(SICI)1097-0231(19990630)13:12<1175::AID-RCM639>3.0.CO;2-0
The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds.
Bonfiglio (1999)
10.1097/FTD.0000000000000059
Measurement of the Direct Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Plasma Using Turbulent Flow Liquid Chromatography With High-Resolution Mass Spectrometry
Tracey Gous (2014)
10.1177/1747493016659671
Measuring non-vitamin K antagonist oral anticoagulant levels: When is it appropriate and which methods should be used?
L. Drouet (2016)
10.1136/heartjnl-2015-309075
Direct oral anticoagulants: unique properties and practical approaches to management
G. Barnes (2016)
10.1111/bcpt.12417
Dabigatran Concentration: Variability and Potential Bleeding Prediction In “Real–Life” Patients With Atrial Fibrillation
P. Šinigoj (2015)
10.1016/j.jchromb.2016.03.022
Ferromagnetic particles as a rapid and robust sample preparation for the absolute quantification of seven eicosanoids in human plasma by UHPLC-MS/MS.
Anna Catharina Suhr (2016)
10.1021/AC020361S
Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS.
B. Matuszewski (2003)
10.1007/s00228-016-2060-y
Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation
F. Al-Aieshy (2016)
10.1124/dmd.108.023143
Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans
Nirmala Raghavan (2009)
10.1016/j.chest.2016.01.021
The Direct Factor Xa Inhibitor Rivaroxaban Passes Into Human Breast Milk.
M. Wiesen (2016)
10.1016/S0140-6736(14)61943-7
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial
C. Ruff (2015)
10.1111/bjh.13810
Laboratory measurement of the direct oral anticoagulants
B. Dale (2016)
Supplemental Material: The online version of this article
10.1016/j.clinbiochem.2008.08.001
Sample preparation for liquid chromatography-tandem mass spectrometry using functionalized ferromagnetic micro-particles.
M. Vogeser (2008)
ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE VIRAL SAFETY EVALUATION OF BIOTECHNOLOGY PRODUCTS DERIVED FROM CELL LINES OF HUMAN OR ANIMAL ORIGIN Q 5 A ( R 1 )
Ich Harmonised (2006)
10.1124/dmd.108.025569
Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans
C. Weinz (2009)
Direct oral anticoagulants ( DOACs ) in the laboratory :
DM Adcock (2015)
10.1016/j.clinbiochem.2014.06.078
Deproteination of whole blood for LC-MS/MS using paramagnetic micro-particles.
D. Van den Bossche (2014)
10.1007/978-1-4939-3252-8_3
Quantitation of the Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Warfarin in Plasma Using Ultra-Performance Liquid Chromatography with Tandem Mass Spectrometry (UPLC-MS/MS).
Jaime H. Noguez (2016)
10.1371/journal.pone.0145478
UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays
J. Kuhn (2015)
Guidance for Industry, Bioanalytical Method Validation, Draft Guidance
U S Fda
10.1111/jth.12702
Determination of dabigatran, rivaroxaban and apixaban by ultra‐performance liquid chromatography – tandem mass spectrometry (UPLC‐MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants
E. M. H. Schmitz (2014)
OF HEALTH AND HUMAN SERVICES Food and Drug Administration
L. Kux (2014)
10.1016/j.thromres.2015.04.030
Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation.
M. Skeppholm (2015)
10.1373/clinchem.2012.198788
Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories.
Tuukka A Helin (2013)
10.1124/dmd.112.046888
Pharmacokinetics, Biotransformation, and Mass Balance of Edoxaban, a Selective, Direct Factor Xa Inhibitor, in Humans
M. Bathala (2012)
10.1016/S0140-6736(15)60245-8
Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs
F. Verheugt (2015)
10.1186/1477-9560-11-10
Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring
W. Mueck (2013)
10.1160/TH15-05-0415
Edoxaban: Impact on routine and specific coagulation assays. A practical laboratory guide.
J. Douxfils (2016)
10.1007/s11239-015-1282-7
Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication
A. Cuker (2015)
10.1016/j.ahj.2016.04.010
NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank.
J. Reiffel (2016)
10.2165/00003088-200544120-00003
Comparative Pharmacokinetics of Vitamin K Antagonists
M. Ufer (2005)



This paper is referenced by
10.1097/FTD.0000000000000594
Pharmacokinetic and Pharmacodynamic Drug Monitoring of Direct-Acting Oral Anticoagulants: Where Do We Stand?
Eberhard Wieland (2018)
10.12793/tcp.2019.27.1.33
Quantification of apixaban in human plasma using ultra performance liquid chromatography coupled with tandem mass spectrometry
Hyeon-Cheol Jeong (2019)
LC-MS/MS ASSAY FOR THE DETERMINATION OF APIXABAN IN HUMAN PLASMA: ITS APPLICATION TO A PHARMACOKINETIC STUDY
Seelam Sharath Chandra (2019)
10.1016/j.jchromb.2020.122095
A UHPLC-MS/MS method to simultaneously quantify apixaban, edoxaban and rivaroxaban in human plasma and breast milk: For emerging lactation studies.
Yating Zhao (2020)
10.1016/j.cca.2018.08.017
Measurement of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma using automated online solid-phase extraction combined with ultra-performance liquid chromatography-tandem mass spectrometry and its comparison with coagulation assays.
J. Kuhn (2018)
10.1177/1469066719875014
Liquid chromatography–tandem mass spectrometry method for determination of rivaroxaban in human plasma and its application to a pharmacokinetic study
K. Shaikh (2019)
10.1016/j.jpba.2020.113109
Development, validation and application of a new HPLC-DAD method for simultaneous quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma.
Filipa Gouveia (2020)
10.1055/S-0043-122701
NOAKs bei adipösen Patienten – kein Problem?
Martin H. J. Wiesen (2018)
10.1515/cclm-2017-0197
Mass spectrometry or immunoassay: est modus in rebus
Giorgia Antonelli (2017)
10.1007/s00228-018-2421-9
Residual rivaroxaban exposure after discontinuation of anticoagulant therapy in patients undergoing cardiac catheterization
M. Wiesen (2018)
10.1016/J.ACA.2019.03.061
Liquid chromatographic methods for the determination of direct oral anticoagulant drugs in biological samples: A critical review.
Filipa Gouveia (2019)
10.1016/j.jpba.2017.10.011
Simultaneous quantification of direct oral anticoagulants currently used in anticoagulation therapy
Kathrin I. Foerster (2018)
10.1016/j.jchromb.2020.122121
Simple LC-MS/MS method using core-shell ODS microparticles for the simultaneous quantitation of edoxaban and its major metabolites in human plasma.
Saki Ariizumi (2020)
10.1016/j.jchromb.2018.09.026
A simple and fast HPLC-MS/MS method for simultaneous determination of direct oral anticoagulants apixaban, dabigatran, rivaroxaban in human plasma.
Jennifer Lagoutte-Renosi (2018)
Semantic Scholar Logo Some data provided by SemanticScholar